CJC-1295 (No DAC)
Technical Monograph
CJC-1295 (without DAC, strictly modified GRF 1-29) is a synthetic analogue of endogenous Growth Hormone Releasing Hormone (GHRH). By incorporating specific amino acid substitutions at positions 2, 8, 15, and 27, the peptide achieves significant resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage.
Mechanism of Action
The peptide functions as a potent agonist of the GHRH receptor in the anterior pituitary. Upon structural binding, it stimulates the adenylyl cyclase/cAMP and phospholipase C pathways simultaneously. This results in the transcription of the GH1 gene and the direct release of growth hormone.
Pharmacological Detail
Selective activation of GHRH-receptors utilizing the required 29-amino-acid active core.
Pharmacodynamics
Restores or accelerates somatotropic axis function. Promotes transcription-level synthesis of GH.
Pharmacokinetics
Without strict DAC conjugation, half-life is restricted to roughly 30 minutes. Represents a significant improvement over natural GHRH (7 minutes).
Preclinical Observations & In Vitro Data
Extensively studied for somatopause reversal and tissue anabolism.
Observed Timeline of Action
| Timeframe | Pharmacological Effect |
|---|---|
| 15-30 mins | Peak plasma action; somatotrope receptor saturation. |
| 1-2 hours | GH spike resolution; return to elevated basal output. |
Abstract Highlights
- Resists rapid degradation by serum DPP-IV via D-Ala substitution at position 2
- Increases basal and pulsatile GH secretion symmetrically
- Synergistically amplifies total GH output when administered with a GHRP
References
Chemical Specifications
Material Handling & Stability
Strict Notice
THIS COMPOUND IS PRODUCED FOR LABORATORY RESEARCH PURPOSES ONLY. NOT FOR HUMAN CONSUMPTION. MATERIAL DATA SHEETS AND LABORATORY GUIDELINES SHOULD BE CONSULTED PRIOR TO HANDLING.